Nasopharyngeal carcinoma (NPC) is the most common head and neck (H&N) cancer in south China, with a yearly incidence rate varying between 15 and 50 cases per 100 000 ([@bib13]). Radiotherapy is the primary treatment modality for non-disseminated NPC ([@bib18]). Currently, the Tumour, Node, and Metastasis (TNM) staging system is the most reliable method for determining treatment strategies and predicting outcome. Moreover, some other clinical and biological features, such as prevertebral space involvement ([@bib27]), tumour volume ([@bib9]), and Epstein--Barr virus DNA in serum ([@bib23]), have been identified as having important value in risk segregation and survival prediction.

In recent years, diagnostic and treatment methods for NPC have undergone tremendous changes. Intensity-modulated radiation therapy (IMRT) in particular has gradually replaced two-dimensional conventional radiotherapy (2D-CRT) as the primary radiotherapy technique based on improved tumour target conformity, as well as superior locoregional control and long-term survival in NPC ([@bib19]; [@bib15]). Therefore, it is of great importance to determine whether the prognostic factors previously identified in patients treated with 2D-CRT can also be applied in the IMRT era.

Perineural invasion (PNI) is a key clinicopathological feature and established adverse prognostic factor in many malignancies, including H&N, colon and rectum, and prostate cancers ([@bib4]; [@bib12]; [@bib20]). Similarly, cranial nerve (CN) involvement has been proven to be a poor prognostic factor in NPC ([@bib5]). According to the 7th Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC) staging system, NPC with CN involvement are classified as T4 ([@bib7]). However, because surgery is not an option in NPC, except as a salvage treatment, CN involvement is assessed by neurological evaluation, which may underestimate the incidence and importance of this key feature of tumour behaviour ([@bib26]; [@bib22]).

Magnetic resonance imaging, which has excellent soft-tissue contrast resolution and multiplanar imaging capability, has been proven to be a valuable tool for detecting and defining the extent of CN invasion in H&N cancers, including NPC ([@bib22]; [@bib25]). We have previously reported that MRI-detected CN invasion had an unfavourable impact on the prognosis of NPC ([@bib22]). However, the prognostic role of MRI-detected CN invasion in NPC treated with IMRT remains unknown. Thus, the aim of the present study was to determine the prognostic value of MRI-detected CN invasion in a large cohort of NPC patients treated with IMRT.

Materials and methods
=====================

Patient characteristics
-----------------------

We retrospectively reviewed the records of all 749 newly diagnosed, biopsy-proven, non-metastatic NPC patients treated using IMRT at Sun Yat-sen University Cancer Center between January 2003 and December 2007. The clinical features of these patients are shown in [Table 1](#tbl1){ref-type="table"}.

All patients completed a pretreatment evaluation including complete patient history, physical examination, hematology and biochemistry profiles, nasopharynx and neck MRI, chest radiography, abdominal ultrasonography, and single photon emission computed tomography (SPECT) whole-body bone scan. Positron emission tomography computed tomography (PET-CT) was performed in 162 of 749 patients (21.6%). All patients were restaged according to the 7th UICC/AJCC staging system. This retrospective study was conducted in compliance with the institutional policy to protect the patients\' private information and was approved by the institutional review board of Sun Yat-Sen University Cancer Center. Informed consent was obtained from all patients.

Imaging protocol
----------------

All patients underwent MRI with a 1.5-T system (General Electric Signa CV/i; General Electric Healthcare, Chalfont St Giles, UK). The region from the suprasellar cistern to the inferior margin of the sternal end of the clavicle was examined with an H&N combined coil. T1-weighted fast spin-echo images in the axial, coronal, and sagittal planes (repetition time, 500--600 ms; echo time, 10--20 ms) and T2-weighted fast spin-echo images in the axial plane (repetition time, 4000--6000 ms; echo time, 95--110 ms) were obtained before injecting the contrast material. After intravenous administration of gadopentetate dimeglumine (Gd-DTPA; Magnevist, Schering, Berlin) at a dose of 0.1 mmol per kg body weight, spin-echo T1-weighted axial and sagittal sequences and spin-echo T1-weighted fat-suppressed coronal sequences were performed sequentially, with parameters similar to those used before Gd-DTPA injection. We used a section thickness of 3 mm for coronal sequences and 5 mm for other sequences; 22-cm field of view; and 320 × 224 matrix.

Image assessment
----------------

Two radiologists specializing in H&N cancers, who were blinded to the clinical findings, evaluated the MRI data separately. Any disagreements were resolved by consensus. Cranial nerve invasion was detected on images that met one of the following criteria: (1) enhancing soft-tissue tumour along the course of the ipsilateral-related nerve, replacing the normal structures of the CN on gadolinium-enhanced T1-weighted images; and (2) perineural spread, defined as an enlargement or abnormal enhancement of the nerve, obliteration of the neural fat pads adjacent to the neurovascular foramina, and neuroforaminal enlargement ([Figure 1](#fig1){ref-type="fig"}) ([@bib22]; [@bib25]). Because CNs in the parapharyngeal space could not be identified as isolated structures on MRI, parapharyngeal space invasion could not be regarded as evidence of CN invasion in our study.

Magnetic resonance imaging findings of CN invasion at the following sites were assessed: extracranial segment of the maxillary nerve (V3), pterygopalatine fossa, foramen rotundum, foramen ovale, pterygoid canal, internal acoustic meatus, jugular foramen, hypoglossal canal, inferior orbital fissure, orbital apex, superior orbital fissure, cavernous sinus segment of CNs III--V2 and VI, trigeminal ganglion, and CNs in the cistern.

Treatment
---------

All patients underwent radical radiation therapy. The nasopharyngeal and upper neck tumour volumes were treated using IMRT for the entire treatment course. The lower neck was treated with a conventional anterior or anteroposterior opposing cervical technique. Further details of the IMRT techniques used at Sun Yat-Sen University Cancer Center have been reported previously ([@bib17]).

During the study period, our institutional guidelines recommended no chemotherapy for stage I to IIA, concurrent chemoradiation therapy for stage IIB, and concurrent chemoradiation therapy with or without neoadjuvant/adjuvant chemotherapy for stage III to IVA--B, as defined by the 6th edition of the UICC/AJCC staging system. In total, 86.2% of stage III and IV patients (424 of 492) received chemotherapy. When possible, salvage treatments, such as intracavitary brachytherapy, surgery, and chemotherapy, were provided in the event of documented relapse or persistent disease.

Follow-up
---------

The median follow-up was 81.4 months (range, 3.1--126.5 months). Each patient was assessed for treatment response and toxicity during (weekly) and after radiotherapy (every 2--3 months during the first 2 years; every 3--6 months during years 3--5). Endoscopy, CT, or MRI scans of the head and neck were performed every 3 months during the first year and annually during years 2--5. Patients with residual or recurrent local disease underwent biopsy to confirm malignancy. Additional tests were ordered when indicated to evaluate for local or distant failure.

Statistical analysis
--------------------

All analyses were performed using SPSS version 20.0 (IBM Corporation, Armonk, NY, USA). We compared the categorical variables in different groups by using the *χ*^2^ test (or Fisher\'s exact test, if indicated). Actuarial rates were estimated by the Kaplan--Meier method; survival curves were compared using the log-rank test ([@bib16]). The following end points were estimated: overall survival (OS), distant metastasis-free survival (DMFS), and locoregional relapse-free survival (LRFS). We calculated OS from the first day of treatment to death. For DMFS and LRFS analyses, we recorded the latencies (i.e., time from the first day of treatment) to the first distant and locoregional failure.

Multivariate analyses with the Cox proportional hazards model were used to test for independent significance by backward elimination of insignificant explanatory variables ([@bib6]). The Cox proportional hazards model was also used to calculate the hazard ratio (HR). The area under the receiver-operating characteristic (ROC) curve was used to assess the predictive validity of MRI-detected CN invasion, based on the method described by [@bib10] and [@bib29]. The criterion for statistical significance was set at *α*=0.05. All *P*-values were based on two-sided tests.

Results
=======

Clinical diagnosis of CN palsies and MRI findings of CN invasion
----------------------------------------------------------------

Of the total 749 patients, 72 (9.8%) patients initially presented with CN palsy. A total of 188 CNs (the three divisions of trigeminal nerve were counted separately) were found to be paralysed, and 32 patients were found to have multiple CN palsies. Of the 72 patients with CN palsy, 71 patients had one or more MRI findings demonstrating CN invasion.

Magnetic resonance imaging evidence of CN invasion was found in 299 (39.9%) patients, all of whom had locally advanced (T3--4) disease. The incidence of MRI-detected CN invasion in T3 patients was significantly lower than in T4 patients (53.4% *vs* 94.0%, *P*\<0.001). The correlation between MRI-detected CN invasion and ipsilateral CN palsy is shown in [Table 2](#tbl2){ref-type="table"}.

Imaging basis of CN palsies
---------------------------

Among the 188 paralysed CNs, 163 (86.7%) were found to have MRI evidence of CN invasion. No MRI evidence of CN invasion was observed in the remaining 25 (13.3%) paralysed CNs. In these 25 CNs, carotid sheath (*n*=2) or retropharyngeal lymph node (*n*=1) invasion could be identified along the course of ipsilaterally paralysed CNs. No tumour could be detected along the course of the remaining paralysed CNs on MRI.

Prognostic value of MRI-detected CN invasion in T3--4 disease
-------------------------------------------------------------

In 432 patients with T3--4 disease, the 5-year OS (75.8% *vs* 87.9%, *P*=0.002), DMFS (73.5% *vs* 86.2%, *P*=0.003), and LRFS (88.2% *vs* 95.9%, *P*=0.012) for patients with MRI-detected CN invasion were significantly lower than the corresponding rates for patients without MRI-detected CN invasion.

Because most T4 patients had MRI evidence of CN invasion, the prognosis of T3 patients with and without MRI-detected CN invasion was also compared. All patients with locally advanced disease (T3 and T4) in this series were classified into three groups: group 1, T3 disease without MRI-detected CN invasion; group 2, T3 disease with MRI-detected CN invasion; and group 3, T4 disease. There was no significant difference between groups 2 and 3 with respect to OS (80.1% *vs* 73.1%, *P*=0.138), DMFS (77.8% *vs* 70.8%, *P*=0.345), and LRFS (87.9% *vs* 89.3%, *P*=0.611; [Figure 2](#fig2){ref-type="fig"}). However, patients in group 2 had significantly lower DMFS (77.8% *vs* 85.9%, *P*=0.047) and LRFS (87.9% *vs* 95.6%, *P*=0.025) than patients in group 1, and trended towards inferior OS (80.1% *vs* 87.7%, *P*=0.063) ([Figure 2](#fig2){ref-type="fig"}).

Multivariate analysis was performed to adjust for various prognostic factors in T3 and T4 disease. The following parameters were included in the Cox proportional hazards model by backward elimination of insignificant explanatory variables: age (⩽50 years *vs* \>50 years), gender, WHO pathology type (I *vs* II amd III), skull base invasion, paranasal sinus involvement, intracranial invasion, infratemporal invasion, orbital invasion, hypopharynx involvement, MRI-detected CN invasion, CN palsy, N classification, and chemotherapy. MRI-detected CN invasion was found to be an independent predictive factor for DMFS (HR, 1.927; 95% CI, 1.116--3.327; *P*=0.019) and LRFS (HR, 2.605; 95% CI, 1.085--6.255; *P*=0.032) rates in locally advanced disease ([Table 3](#tbl3){ref-type="table"}). Patients with MRI-detected CN invasion also had an increased risk of death, this difference was marginally significant (HR, 1.592; 95% CI, 0.942--2.689; *P*=0.082; [Table 3](#tbl3){ref-type="table"}).

Difference in the prognostic implications between clinical CN palsy and MRI-detected CN invasion
------------------------------------------------------------------------------------------------

In the 300 patients with clinical or MRI-detected CN invasion, no significant difference was observed in 5-year DMFS (70.7% *vs* 74.4%, *P*=0.662) or LRFS (85.4% *vs* 89.2%, *P*=0.289) between patients with and without clinical CN palsy. A marginally significant difference was observed in the 5-year OS (70.8% *vs* 77.5%, *P*=0.053) rate.

The prognostic validity of adding MRI-detected CN invasion to T classification in NPC
-------------------------------------------------------------------------------------

Receiver-operating characteristic curves were used to evaluate the prognostic validity of adding MRI-detected CN invasion to the T classification of TNM staging system. In the 749 patients with NPC, the AUC significantly increased when MRI-detected CN invasion was added to the T classification regarding death (0.663 *vs* 0.651, *P*=0.015; [Figure 3A](#fig3){ref-type="fig"}), DM (0.661 *vs* 0.648, *P*=0.021; [Figure 3B](#fig3){ref-type="fig"}), and locoregional recurrence (0.638 *vs* 0.619, *P*=0.008; [Figure 3C](#fig3){ref-type="fig"}). These results reveal that, in predicting outcomes, the combination of MRI-detected CN invasion and T classification was superior to T classification alone. To classify NPC with cranial nerve involvement (clinical palsy or MRI-detected invasion) as T4 warrants further consideration in the future revision of the current TNM staging system.

Discussion
==========

Perineural invasion has been described in the literature since the mid-1800s but has received relatively little research attention ([@bib21]). In H&N cancers, PNI is a well-recognised prognostic factor and an important indication for adjuvant chemoradiotherapy or radiotherapy after surgery ([@bib4]). Cranial nerve palsy is common in locally advanced NPC, which clearly indicates the existence of neural invasion. However, PNI is often insidious and asymptomatic, especially in the early stages ([@bib26]). It was not until the advent of cross-sectional imaging (CT and MRI) that the comprehensive study of PNI in NPC became possible. Consistent with the results of previous studies, our results showed that the incidence of CN invasion detected by MRI was much higher than that of clinical CN palsy ([@bib26]; [@bib22]). Furthermore, we demonstrated that MRI-detected CN invasion, whether symptomatic or asymptomatic, still indicated poorer survival in locally advanced NPC in the IMRT era, and combining MRI-detected CN invasion with the current T classification resulted in better prediction of death, DM, and locoregional recurrence.

The underlying mechanisms behind PNI are not fully understood. For the past 40 years, the predominant theory behind the pathogenesis of PNI has been that tumour cells spreading along neural sheaths are privileged with low resistance ([@bib21]). However, recent studies have revealed that PNI may involve active reciprocal signalling interactions between tumour cells and nerves and that these invading tumour cells may have acquired the ability to respond to proinvasive signals within the peripheral nerve milieu ([@bib21]). In a PNI model using mouse dorsal root ganglia (DRG) cocultured in a Matrigel matrix with prostate cancer cells, [@bib2]demonstrated tumour cell migration along neurites towards the ganglia of origin as well as focused, directional outgrowth of neurites towards cancer cell colonies. Moreover, the growth of cancer cells and neurite outgrowth of DRG cells was elevated when cultured together ([@bib2]).

There is a growing body of literature reporting neurotrophic factor involvement in cancer and its association with PNI ([@bib28]; [@bib21]). [@bib14] reported that preventive or late administration of anti-nerve growth factor therapy attenuates tumour-induced nerve sprouting, neuroma formation, and cancer pain in a mouse model of prostate cancer. [@bib3] demonstrated *in vitro* and *in vivo* that radiation impairs PNI through downregulating the expression of glial-derived neurotrophic factor by DRG and inhibiting cancer cell viability. Taken together, these results strongly suggest that PNI is not only just a route of tumour spread but also a marker of aggressive tumour behaviour ([@bib28]). This may explain the propensity of NPC to spread through neural foraminas and the prognostic value of MRI-detected CN invasion in NPC.

As non-disseminated NPC was not treated by surgery, we were not able to correlate pathological examination with MRI-detected CN invasion, which was the major limitation of our study. However, MRI evidences of CN invasion along the course of paralysed nerves were found in most cases (86.7%). Moreover, by comparing the results of MRI with postoperative pathological examination, [@bib11] proved that MRI had a very satisfactory sensitivity (100%) and specificity (85%) for detecting perineural spread of adenoid cystic carcinoma of the H&N to the skull base, which is comparable to other reports in H&N cancer ([@bib8]).

To the best of our knowledge, herein is the first evidence demonstrating the prognostic value of MRI-detected CN invasion in NPC treated with IMRT. Our results show that patients with MRI-detected CN invasion experienced more recurrences and distant metastases, which suggested that current chemoradiotherapy strategies might not be sufficient for this subset of patients. Further studies are required to develop more intensive systemic approaches combined with IMRT to improve the outcome of these patients. Moreover, researchers have proven that antineurotrophin therapy was effective in breast, prostate, and pancreatic cancer *in vivo* ([@bib24]; [@bib1]). The therapeutic potential of this novel strategy in NPC with CN invasion needs to be addressed in the future.

In conclusion, MRI-detected CN invasion is common in NPC and often seen in asymptomatic patients. MRI-detected CN invasion confers poorer prognoses in NPC patients treated with IMRT. Future studies are warranted to reveal the latent mechanism behind CN invasion and to develop more effective treatment strategies in NPC patients with MRI-detected CN invasion.
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![**Enhanced, coronal, T1-weighted, fat-suppression magnetic resonance (MR) images (repetition time, 600 ms; echo, 15 ms) of patients with nasopharyngeal carcinoma.** (**A**) A patient with left CN V3 palsy. Image shows perineural invasion via the enlarged right foramen ovale along V3 (long arrow) and into the cavernous sinus. The main branch of the V3 on the right is normal (short arrow). (**B**) A patient with right CN V2 palsy. Image shows enlargement of the right foramen rotundum and enhancement of the right V2 (long arrow). The left foramen rotundum and V2 is normal (short arrow). (**C**) A patient with left CN V1 palsy. Image shows abnormal enhancement of the left V1 (white arrowhead) and enlargement and enhancement of the left pterygoid canal (long arrow). Note that the left V2 (black arrowhead) and the right pterygoid canal (short arrow) is not involved. (**D**) A patient without clinical CN palsy. Image shows abnormal enhancement of the right Gasser\'s ganglion (long arrow). The left Gasser\'s ganglion is not involved (short arrow).](bjc201427f1){#fig1}

![**Kaplan--Meier survival curves for overall survival (**A**), distant metastasis-free survival (**B**), and locoregional relapse-free survival (**C**) in different groups: group 1, T3 disease without MRI-detected CN invasion; group 2, T3 disease with MRI-detected CN invasion; group 3, T4 disease.** *P*-values were calculated with the unadjusted log-rank test. Abbreviations: CN=Cranial nerve; MRI=Magnetic resource imaging.](bjc201427f2){#fig2}

![**Receiver-operating characteristic curves for the outcome prediction of T classification alone and the combination of magnetic resonance imaging (MRI)-detected CN invasion and T classification in NPC (*n*=749), with death (**A**), distant metastasis (**B**), and locoregional recurrence (**C**) as the end point.** The *P*-values were compared with the T classification alone. \*Magnetic resonance imaging--detected CN invasion combined with T classification. Abbreviations: AUC=area under the curve; CN=Cranial nerve; MRI=Magnetic resource imaging.](bjc201427f3){#fig3}

###### Clinical features of the 749 NPC patients in the study

  **Characteristic**                          **No. of patients (%)**
  ------------------------------------------- -------------------------
  **Age (years)**                             
  \>50                                        553 (73.8)
  ⩽50                                         196 (26.2)
  **Gender**                                  
  Male                                        580 (77.4)
  Female                                      169 (22.6)
  **WHO pathology**                           
  Type I                                      5 (0.7)
  Type II/III                                 744 (99.3)
  **Chemotherapy**                            
  Yes                                         535 (71.4)
   Concurrent chemoradiotherapy               233 (31.1)
   Neoadjuvant+concurrent chemoradiotherapy   246 (32.8)
   Concurrent chemoradiotherapy+adjuvant      46 (8.6)
  No                                          214 (28.6)
  **T category[a](#t1-fn2){ref-type="fn"}**   
  T1                                          177 (23.6)
  T2                                          140 (18.7)
  T3                                          264 (35.2)
  T4                                          168 (22.4)
  **N category[a](#t1-fn2){ref-type="fn"}**   
  N0                                          184 (24.6)
  N1                                          409 (54.6)
  N2                                          106 (14.2)
  N3                                          50 (6.7)
  **Stage[a](#t1-fn2){ref-type="fn"}**        
  I                                           78 (10.4)
  II                                          179 (23.9)
  III                                         282 (37.7)
  IV                                          210 (28.0)

Abbreviations: AJCC=American Joint Committee on Cancer; N=node; NPC=nasopharyngeal carcinoma; T=tumour; UICC=Union for International Cancer Control; WHO=World Health Organization.

According to the 7th UICC/AJCC staging system.

###### The correlation between MRI-detected cranial nerve invasion and the ipsilateral-related cranial nerve palsy

  **Sites of MRI-detected CN invasion**   **No.**   **Ipsilateral palsied cranial nerve no.**
  --------------------------------------- --------- -------------------------------------------
  **Basicranial or extracranial**                   
  Pterygopalatine fossa                   161       V2, 22
  Rotundum foramen                        71        V2, 21
  Extracranial part of V3                 116       V3, 19
  Ovale foramen                           83        V3, 17
  Internal acoustic meatus                1         VIII, 0
  Jugular foramen                         23        IX, 4; X, 5; XI, 2
  Hypoglossal foramen                     82        XII, 7
  Pterygoid canal                         185       ---
  **Intracranial or orbital**                       
  Superior orbital fissure                4         III, 1; IV, 1; V1, 1; VI, 2
  Orbital apex                            5         II, 2
  Inferior orbital fissure                42        V2, 17
  Cavernous segment of III                17        III, 4
  Cavernous segment of IV                 29        IV, 5
  Cavernous segment of V1                 79        V1, 15
  Cavernous segment of V2                 88        V2, 27
  Cavernous segment of VI                 46        VI, 20
  Trigeminal ganglion                     81        V, 27
  Cisternal part of V                     12        V, 10
  Cisternal part of IX--XII               9         IX, 1; X, 2; XI, 0; XII, 2

Abbreviations: CN=cranial nerve; MRI=magnetic resonance imaging.

###### Multivariate analyses of prognostic factors for patients with T3--4 nasopharyngeal carcinoma (*n*=432)

  **End point**   **Variable**                            ***P*-value**[a](#t3-fn2){ref-type="fn"}   **HR**   **95% CI for HR**
  --------------- --------------------------------------- ------------------------------------------ -------- -------------------
  OS              MRI-detected CN invasion                0.082                                      1.592    0.942--2.689
                  Age                                     \<0.001                                    2.160    1.471--3.172
                  Intracranial invasion                   0.022                                      1.630    1.072--2.479
                  Orbital invasion                        0.070                                      1.662    0.959--2.878
                  N category[b](#t3-fn3){ref-type="fn"}   0.043                                      1.557    1.014--2.391
  DMFS            MRI-detected CN invasion                0.019                                      1.927    1.116--3.327
                  Intracranial invasion                   0.036                                      1.583    1.031--2.429
                  N category[b](#t3-fn3){ref-type="fn"}   0.001                                      2.060    1.346--3.153
  LRFS            MRI-detected CN invasion                0.032                                      2.605    1.085--6.255
                  Orbital invasion                        0.075                                      2.113    0.928--4.813

Abbreviations: AJCC=American Joint Committee on Cancer; CI=confidence interval; CN=cranial nerve; DMFS=distant metastasis-free survival; HR=hazard ratio; LRFS=locoregional relapse-free survival; MRI=magnetic resonance imaging; N=node; OS=overall survival; T=tumour; UICC=Union for International Cancer Control.

*P*-values were calculated with an adjusted Cox proportional hazards model.

According to the 7th UICC/AJCC staging system.
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